Role of mannose binding lectin (MBL) complement activation pathway, an arm of innate immunity in multiple sclerosis (MS) was evaluated by analyzing the expression of MBL, MBL-associated serine protease-2 (MASP-2), and functional MBL/MASP-2 mediated C4 cleavage (fMBL) in 87 plasma and cerebrospinal fluid (CSF) samples from MS patients and non-MS controls. Median fMBL and MASP-2 plasma levels were higher in MS vs. non-MS cases. These associations remained in an analysis of subtypes of MS disease. These findings suggest a potential activation of MBL complement pathway in MS that may possibly alter the risk or progression of MS disease.
Introduction
Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination of the central nervous system (CNS) (Petersen et al., 2009 ). About 1.1 million people worldwide and about 400,000 of them live with MS in the United States. MS is considered a multi-factorial disease including viral infection (e.g., herpes simplex virus), genetic factors, and an impairment of the immune system (Hogancamp et al., 1997) . MS linked autoimmunity has been mostly attributed to adaptive immune system dysfunction (Kasper and Shoemaker, 2010) . However, innate immune system may play a crucial role in the pathogenesis of MS (Waldner, 2009) . MS associated demyelination can be induced by direct complement activation after its binding to the myelin, which may result in the damage and lysis of oligodendrocyte and also in the chemoattraction and infiltration of macrophages.
Mannose binding lectin (MBL) is primarily synthesized in the liver and is distributed throughout the body via the bloodstream. MBL binds to mannose residues present on the surface of a pathogen, activates the MBL-associated serine protease-2 (MASP-2) and leads to C3 activation, MBL-mediated opsonization and phoagocytosis of the pathogen (Garred, 2008) . A critical injury of the CNS may also initiate complement activation in MS disease. A neuroinflammatory response to a CNS injury may also result in MS related neurodegeneration (Yong and Marks, 2010) .
In this study, we determined the expression of MBL, MASP-2 and functional MBL (MBL/MASP-2 mediated C4 cleavage activity) in plasma and cerebrospinal fluids from multiple sclerosis patients and analyzed their association with the MS disease.
Material and methods

Study population
20 samples each of blood and cerebrospinal fluid from subjects with varying degrees of multiple sclerosis were obtained from Human Brain and Spinal Fluid Resource Center, Los Angeles, CA. 29 plasma and 7 CSF samples from control non-MS subjects were used. Subjects were on several medications including steroids, estrogen, betaseron, extavia, avonex, baclofen, copaxone, natalizumab (Tysabri), ibuprofen, multivitamins, etc.
Multiple sclerosis primary progressive (MS1 P) disease was classified as primary progressive MS disease with no relapses, while MS secondary progressive (MS2 P) disease was classified as secondary progressive MS with or without relapses. MS 2 progressive with relapse (MS2 PR) was classified as secondary progressive MS with relapses in the last 2 years; and MS PRPS was classified as progressive relapsing MS disease that started initially as primary progressive but later had relapses. MS relapsing/remitting in remission (MS RR) was classified by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery).
